Anti-chitinase-3-like protein-1 (YKL-40) neutralizing antibody and uses thereof
AssigneeInstitute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.
InventorsMing-Cheng Chang, Ping-Fang Chiang, Yu-Jen Kuo
Life of this patent
Estimating the term…
Abstract
Disclosed herein an isolated neutralizing antibody, which is capable of specifically binding to chitinase-3-like protein-1 (YKL-40) and uses thereof. The neutralizing antibody can further conjugate with a metal chelator to form an antibody complex. Further, labeling the antibody complex with a radioactive metal nuclide results in formation of a radioactive antibody complex, which can be used as a contrast agent and treatment for YKL-40 over-expression-related diseases. The radioactive antibody complex can specifically bind to YKL-40, and can be used for diagnosis and the preparation of the use of the treatment for cancers related to YKL-40 over-expression.
Claims19
An isolated neutralizing antibody that specifically binding to YKL-40, wherein the isolated neutralizing antibody comprising:
- a heavy chain variable region (VH) comprising a CDR1 domain comprising the amino acid sequence of GYTFPNYGMN (SEQ ID NO:
- 1), a CDR2 domain comprising the amino acid sequence of WINTYTGEPTYTVDFKG (SEQ ID NO:
- 2), and a CDR3 domain comprising the amino acid sequence of ARSFYGTNGFDY (SEQ ID NO:
- 3);
- and
- a light chain variable region (VL) comprising a CDR1 domain comprising the amino acid sequence of KASENVGTYVS (SEQ ID NO:
- 4), a CDR2 domain comprising the amino acid sequence of GASNRYI (SEQ ID NO:
- 5), and a CDR3 domain comprising the amino acid sequence of GQSYSYPPT (SEQ ID NO:
- 6).
Dependencies are inferred from the claim text.